LONDON — GSK said Tuesday it would buy RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.
GSK is paying $58 per share for the South San Francisco biotech, a roughly 65% premium on Rapt’s closing price on Friday.
The centerpiece of the deal is ozureprubart, an antibody designed to protect people from food allergens. The medicine is in a Phase 2 trial, with data expected in 2027. It targets an immune molecule known as IgE that is involved in allergic reactions. Continue to STAT+ to read the full story…